使用二维 (2D) 二极管阵列 MapCHECK2 为复杂的放射治疗计划进行多叶准直器建模和调试。

IF 2.7 4区 医学 Q3 ONCOLOGY Technology in Cancer Research & Treatment Pub Date : 2024-01-01 DOI:10.1177/15330338231225864
Jian Guo, Meng Zhu, Weijin Zeng, He Wang, Songbing Qin, Zhibin Li, Yu Tang, Binbin Ying, Jiugao Sang, Ming Ji, Kuo Meng, Zhouguang Hui, Jianyang Wang, Juying Zhou, Yin Zhou, Jian Huan
{"title":"使用二维 (2D) 二极管阵列 MapCHECK2 为复杂的放射治疗计划进行多叶准直器建模和调试。","authors":"Jian Guo, Meng Zhu, Weijin Zeng, He Wang, Songbing Qin, Zhibin Li, Yu Tang, Binbin Ying, Jiugao Sang, Ming Ji, Kuo Meng, Zhouguang Hui, Jianyang Wang, Juying Zhou, Yin Zhou, Jian Huan","doi":"10.1177/15330338231225864","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> This study aims to develop a data-collecting package ExpressMLC and investigate the applicability of MapCHECK2 for multileaf collimator (MLC) modeling and commissioning for complex radiation treatment plans. <b>Materials and methods:</b> The MLC model incorporates realistic parameters to account for sophisticated MLC features. A set of 8 single-beam plans, denoted by ExpressMLC, is created for the determination of parameters. For the commissioning of the MLC model, 4 intensity modulated radiation therapy (IMRT) plans specified by the AAPM TG 119 report were transferred to a computed tomography study of MapCHECK2, recalculated, and compared to measurements on a Varian accelerator. Both per-beam and composite-beam dose verification were conducted. <b>Results:</b> Through sufficient characterization of the MLC model, under 3%/2 mm and 2%/2 mm criteria, MapCHECK2 can be used to accurately verify per beam dose with gamma passing rate better than 90.9% and 89.3%, respectively, while the Gafchromic EBT3 films can achieve gamma passing rate better than 89.3% and 85.7%, respectively. Under the same criteria, MapCHECK2 can achieve composite beam dose verification with a gamma passing rate better than 95.9% and 90.3%, while the Gafchromic EBT3 films can achieve a gamma passing rate better than 96.1% and 91.8%; the <i>p</i>-value from the Mann Whitney test between gamma passing rates of the per beam dose verification using full MapCHECK2 package calibrated MLC model and film calibrated MLC model is .44 and .47, respectively; the <i>p</i>-value between those of the true composite beam dose verification is .62 and .36, respectively. <b>Conclusion:</b> It is confirmed that the 2-dimensional (2D) diode array MapCHECK2 can be used for data collection for MLC modeling with the combination of the ExpressMLC package of plans, whose doses are sufficient for the determination of MLC parameters. It could be a fitting alternative to films to boost the efficiency of MLC modeling and commissioning without sacrificing accuracy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"23 ","pages":"15330338231225864"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846010/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multileaf Collimator Modeling and Commissioning for Complex Radiation Treatment Plans Using 2-Dimensional (2D) Diode Array MapCHECK2.\",\"authors\":\"Jian Guo, Meng Zhu, Weijin Zeng, He Wang, Songbing Qin, Zhibin Li, Yu Tang, Binbin Ying, Jiugao Sang, Ming Ji, Kuo Meng, Zhouguang Hui, Jianyang Wang, Juying Zhou, Yin Zhou, Jian Huan\",\"doi\":\"10.1177/15330338231225864\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> This study aims to develop a data-collecting package ExpressMLC and investigate the applicability of MapCHECK2 for multileaf collimator (MLC) modeling and commissioning for complex radiation treatment plans. <b>Materials and methods:</b> The MLC model incorporates realistic parameters to account for sophisticated MLC features. A set of 8 single-beam plans, denoted by ExpressMLC, is created for the determination of parameters. For the commissioning of the MLC model, 4 intensity modulated radiation therapy (IMRT) plans specified by the AAPM TG 119 report were transferred to a computed tomography study of MapCHECK2, recalculated, and compared to measurements on a Varian accelerator. Both per-beam and composite-beam dose verification were conducted. <b>Results:</b> Through sufficient characterization of the MLC model, under 3%/2 mm and 2%/2 mm criteria, MapCHECK2 can be used to accurately verify per beam dose with gamma passing rate better than 90.9% and 89.3%, respectively, while the Gafchromic EBT3 films can achieve gamma passing rate better than 89.3% and 85.7%, respectively. Under the same criteria, MapCHECK2 can achieve composite beam dose verification with a gamma passing rate better than 95.9% and 90.3%, while the Gafchromic EBT3 films can achieve a gamma passing rate better than 96.1% and 91.8%; the <i>p</i>-value from the Mann Whitney test between gamma passing rates of the per beam dose verification using full MapCHECK2 package calibrated MLC model and film calibrated MLC model is .44 and .47, respectively; the <i>p</i>-value between those of the true composite beam dose verification is .62 and .36, respectively. <b>Conclusion:</b> It is confirmed that the 2-dimensional (2D) diode array MapCHECK2 can be used for data collection for MLC modeling with the combination of the ExpressMLC package of plans, whose doses are sufficient for the determination of MLC parameters. It could be a fitting alternative to films to boost the efficiency of MLC modeling and commissioning without sacrificing accuracy.</p>\",\"PeriodicalId\":22203,\"journal\":{\"name\":\"Technology in Cancer Research & Treatment\",\"volume\":\"23 \",\"pages\":\"15330338231225864\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846010/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Technology in Cancer Research & Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/15330338231225864\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology in Cancer Research & Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15330338231225864","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在开发一个数据收集软件包 ExpressMLC,并研究 MapCHECK2 在多叶准直仪(MLC)建模和复杂放射治疗计划调试中的适用性。材料和方法:多叶准直仪模型包含现实参数,以考虑复杂的多叶准直仪特征。为确定参数,创建了一组 8 个单光束计划(以 ExpressMLC 表示)。为了调试 MLC 模型,将 AAPM TG 119 报告中指定的 4 个调强放射治疗(IMRT)计划转移到 MapCHECK2 的计算机断层扫描研究中,重新计算,并与瓦里安加速器上的测量结果进行比较。对每个光束和复合光束的剂量都进行了验证。结果:通过对 MLC 模型的充分表征,在 3%/2 mm 和 2%/2 mm 标准下,MapCHECK2 可用于精确验证每束剂量,伽马通过率分别优于 90.9% 和 89.3%,而 Gafchromic EBT3 薄膜的伽马通过率分别优于 89.3% 和 85.7%。在相同标准下,MapCHECK2 可实现伽马通过率优于 95.9% 和 90.3% 的复合射束剂量验证,而 Gafchromic EBT3 薄膜可实现伽马通过率优于 96.1% 和 91.8%;使用全 MapCHECK2 软件包校准的 MLC 模型和薄膜校准的 MLC 模型进行每束剂量验证的伽马通过率之间的曼-惠特尼检验的 p 值分别为 0.44 和 0.47;真实复合束剂量验证的 p 值分别为 0.62 和 0.36。结论二维(2D)二极管阵列 MapCHECK2 可用于 MLC 建模的数据收集,并与 ExpressMLC 计划包相结合,其剂量足以确定 MLC 参数。它可以替代薄膜,在不影响精度的情况下提高 MLC 建模和调试的效率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Multileaf Collimator Modeling and Commissioning for Complex Radiation Treatment Plans Using 2-Dimensional (2D) Diode Array MapCHECK2.

Purpose: This study aims to develop a data-collecting package ExpressMLC and investigate the applicability of MapCHECK2 for multileaf collimator (MLC) modeling and commissioning for complex radiation treatment plans. Materials and methods: The MLC model incorporates realistic parameters to account for sophisticated MLC features. A set of 8 single-beam plans, denoted by ExpressMLC, is created for the determination of parameters. For the commissioning of the MLC model, 4 intensity modulated radiation therapy (IMRT) plans specified by the AAPM TG 119 report were transferred to a computed tomography study of MapCHECK2, recalculated, and compared to measurements on a Varian accelerator. Both per-beam and composite-beam dose verification were conducted. Results: Through sufficient characterization of the MLC model, under 3%/2 mm and 2%/2 mm criteria, MapCHECK2 can be used to accurately verify per beam dose with gamma passing rate better than 90.9% and 89.3%, respectively, while the Gafchromic EBT3 films can achieve gamma passing rate better than 89.3% and 85.7%, respectively. Under the same criteria, MapCHECK2 can achieve composite beam dose verification with a gamma passing rate better than 95.9% and 90.3%, while the Gafchromic EBT3 films can achieve a gamma passing rate better than 96.1% and 91.8%; the p-value from the Mann Whitney test between gamma passing rates of the per beam dose verification using full MapCHECK2 package calibrated MLC model and film calibrated MLC model is .44 and .47, respectively; the p-value between those of the true composite beam dose verification is .62 and .36, respectively. Conclusion: It is confirmed that the 2-dimensional (2D) diode array MapCHECK2 can be used for data collection for MLC modeling with the combination of the ExpressMLC package of plans, whose doses are sufficient for the determination of MLC parameters. It could be a fitting alternative to films to boost the efficiency of MLC modeling and commissioning without sacrificing accuracy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
202
审稿时长
2 months
期刊介绍: Technology in Cancer Research & Treatment (TCRT) is a JCR-ranked, broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.
期刊最新文献
A 3 M Evaluation Protocol for Examining Lymph Nodes in Cancer Patients: Multi-Modal, Multi-Omics, Multi-Stage Approach Prognostic Value of IGFBP6 in Breast Cancer: Focus on Glucometabolism The Antimicrobial Peptide Merecidin Inhibit the Metastasis of Triple-Negative Breast Cancer by Obstructing EMT via miR-30d-5p/Vimentin Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma Retracted: “CRISPR/Cas9: A Revolutionary Genome Editing Tool for Human Cancers Treatment”
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1